Join Us For This Online Webinar: What's Next? - Managing Myeloma at Relapse (https://www.myeloma.org/videos/imf-virtual-mcw-whats-next-managing-myeloma-relapse-2026)
Register NOW for the FREE IMF Virtual Myeloma Community Workshop
August 24, 2026
3:00 PM PT / 4:00 PM MT
5:00 PM CT / 6:00PM ET
The Virtual Myeloma Community Workshop will focus on topics concerning relapsed/refractory myeloma patients. Learn more about treatment response, disease progression and management approaches at time of relapse. We will review treatment strategies, the importance of clinical trials, symptom management, and being a part of treatment decision making to help you live your best life with myeloma. After each presentation with the experts, attendees will have ample time to ask questions.
Welcome and Introductions
Robin Tuohy, 26-year Myeloma Care Partner
IMF, Vice President, Patient Support
What is Relapse and How do we Deal with it?
Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO
IMF Medical Advisor
(TGen, City of Hope—Phoenix, AZ)
What are the Key Treatments we have for Relapsed Myeloma?
Betsy O’Donnell, MD
Dana-Farber Cancer Institute—Boston, MA)
CAR-T Cell Therapy: What it is and How we deliver it
Luciano Costa, MD
University of Alabama Medicine, The Kirklin Clinic, Birmingham, AL
Myeloma: Putting the Pieces of the Puzzle Together
Patricia Mangan, RN, MSN, APRN-BC
IMF Nurse Leadership Board Member
(University of Pennsylvania, Abramson Cancer Center — Philadelphia, PA )
Faculty Roundtable: The Importance of Clinical Trials
Q&A with Panel
Closing Remarks
Additional Resources:
Download the IMF's Multiple Myeloma Informational Booklets:
Download IMF publications (https://www.myeloma.org/cancer-information-series)
What Is a Clinical Trial? (https://www.myeloma.org/clinical-trials)
*Of note, Venetoclax has already been approved to treat acute myeloid leukemia, chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in adults and is now being evaluated to treat other types of cancers, including multiple myeloma. It is part of a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors that work by blocking the action of BCL-2 (a protein in the body that regulates cell death). Trials using Venetoclax were discussed in this webinar. You can learn about these three trials at the following links:
- CANOVA Clinical Trial Fact Sheet (https://imf-d8-prod.s3.us-west-1.wasabisys.com/2021-08/CTFS_Venetoclax%20CANOVA_M13-494_NCT03539744_a3.pdf)
clinicaltrials.gov Identifier: NCT03539744 - Phase II Relapsed or Refractory Venetoclax Trial (https://imf-d8-prod.s3.us-west-1.wasabisys.com/2021-08/CTFS_Venetoclax_M15-338_NCT02899052_a3.pdf)
clinicaltrials.gov Identifier: NCT02899052 - Phase I/II Trial Using a Venetoclax Combination With or Without Bortezomib (https://imf-d8-prod.s3.us-west-1.wasabisys.com/2021-08/CTFS_Venetoclax_M15-654_NCT03314181_a3.pdf)
clinicaltrials.gov Identifier: NCT03314181